Article
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma
2023-10-01
Abstract excerpt
Lung adenocarcinoma (LUAD), commonly driven by KRAS mutations, is responsible for 7% of all cancer mortality. The first allele-specific KRAS inhibitors were recently approved in LUAD, but clinical benefit is limited by intrinsic and acquired resistance. LUAD predominantly arises from alveolar type 2 (AT2) cells, which function as facultative alveolar stem cells by self-renewing and replacing alveolar type 1 (AT1)...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f6d9c349-4360-53bd-af36-3f26d07df383
- DOI
- 10.1101/2023.09.29.560194
